Xu Yi, Zhu Jianyong, Lei Zhangming, Wan Lijun, Zhu Xiuwen, Ye Feng, Tong Yanyue
Department of Urology, Quzhou People's Hospital Quzhou 324000, Zhejiang, China.
Int J Clin Exp Pathol. 2015 Nov 1;8(11):14161-70. eCollection 2015.
microRNAs (miRNAs) play essential roles in many tumors, including renal cell carcinoma (RCC). The aim of the present study was to investigate the expression and functional role of miR-29b in RCC and to identify its target genes.
We determined the expression of miR-29b in clear cell RCC (ccRCC) tissues and RCC cell lines (786-O, A498, and SN12-PM6) using quantitative real-time PCR (qRT-PCR). The associations between miR-29b expression and clinical pathological parameters and prognosis were explored. Besides, the role of miR-29b in the SN12-PM6 cells proliferation, apoptosis, cycle, and invasion were investigated after transduction with lentivirus vectors. The kines in family member 1B (KIF1B), possible miR-29b target genes, were predicted using bioinformatics approaches, as well as the role in the pathogenesis of RCC.
Elevated expression of miR-29b was found in both tumor tissues and cell lines. High expression of miR-29b was significantly associated with tumor-node-metastasis (TNM) stage (P = 0.026) and the overall survival (P = 0.009) in the ccRCC. Inhibition of miR-29b expression could promote apoptosis, and inhibit proliferation and invasion ability in SN12-PM6 cells. Also, we confirmed that miR-29b could directly regulate the expression of KIF1B at the post transcriptional level.
These data suggest that miR-29b acts as an oncomiR, promoting proliferation and invasion ability through KIF1B suppression, and it might be a potential marker for prognosis of RCC.
微小RNA(miRNA)在包括肾细胞癌(RCC)在内的许多肿瘤中发挥重要作用。本研究旨在探讨miR-29b在RCC中的表达及其功能作用,并鉴定其靶基因。
我们使用定量实时PCR(qRT-PCR)测定了miR-29b在透明细胞RCC(ccRCC)组织和RCC细胞系(786-O、A498和SN12-PM6)中的表达。探讨了miR-29b表达与临床病理参数及预后之间的关系。此外,在用慢病毒载体转导后,研究了miR-29b在SN12-PM6细胞增殖、凋亡、周期和侵袭中的作用。使用生物信息学方法预测了可能的miR-29b靶基因驱动蛋白家族成员1B(KIF1B)以及其在RCC发病机制中的作用。
在肿瘤组织和细胞系中均发现miR-29b表达升高。miR-29b的高表达与ccRCC的肿瘤-淋巴结-转移(TNM)分期(P = 0.026)和总生存期(P = 0.009)显著相关。抑制miR-29b表达可促进SN12-PM6细胞凋亡,并抑制其增殖和侵袭能力。此外,我们证实miR-29b可在转录后水平直接调节KIF1B的表达。
这些数据表明,miR-29b作为一种癌基因miRNA,通过抑制KIF1B促进增殖和侵袭能力,它可能是RCC预后的潜在标志物。